<DOC>
	<DOC>NCT03050229</DOC>
	<brief_summary>To explore the beneficial effects of 'empagliflozin + ARB' in comparison with 'placebo + ARB' on the reduction of nocturnal blood pressure in T2DM with hypertension</brief_summary>
	<brief_title>SGLT-2i and ARB Combination Therapy in Patients With T2DM and Nocturnal Hypertension (SACRA Study)</brief_title>
	<detailed_description>The study consists of a 8-week run-in period and a 12-week treatment period.</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<criteria>Patients who meet the following criteria at the start of treatment are eligible for the study: Receiving stable treatment with antihypertensive including ARB for at least 8 weeks at baseline (0W). Receiving stable antidiabetic treatment with/without antidiabetics for at least 8 weeks at baseline (0W). HbA1c&gt;=6.0%, &lt;10% Seated office SBP 130159mmHg or DBP 8099mmHg Nocturnal hypertension (SBP&gt;=115 mmHg) as measured by Home BP during 5days before baseline (0W). Age&gt;=20 Patients who meet any of the following criteria are not eligible for the study: History of hypersensitivity to empagliflozin Breastfeeding, pregnant, possibly pregnant, or plan to become pregnant Treated with insulin or SU With renal dysfunction (eGFR&lt;45mL/min/1.73m2) With liver dysfunction (AST or ALT is 3 times higher than reference value) Hypotension (systolic blood pressure &lt; 90 mmHg) With pituitary gland dysfunction or adrenal gland dysfunction Heart failure patients whose NYHA class is IV Deemed ineligible for the study due to another reason by investigator History of diabetic ketoacidosis or diabetic come within 3 months before enrollment History of Acute myocardial infarction, unstable angina, cerebrovascular disease, or transient ischemic attack within 3 months before enrollment Patients who have undergone percutaneous transluminal coronary angioplasty (PCI) or coronary artery bypass graftin (CABG) within 3 months before enrollment Patients received SGLT2 inhibitor within 8 weeks before enrollment</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>